GABARAP is a clinically relevant binding partner of CRT. (A) Schematic representation of the analysis combining proteomic and transcriptomic data. (B-C) Prognostic relevance (overall survival [OS] [B] or progression-free survival [PFS] [C]) of low GABARAP level estimated in patients enrolled in the IFM/DFCI. P value was calculated with a log-rank test. (D-E) Same analysis as in panels B and C but excluding patients from the IFM/DFCI carrying 17p deletion. P value was calculated with a log-rank test. (F-G) Immunoblot of GABARAP, CRT, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) on total protein lysates or proteins bound to CRT or Immunoglobulin G isotype control in AMO1 cells untreated or treated with BTZ (5 nM; 10 hours) (F) or CFZ (10 nM, 16 hours) (G). (H) Representative confocal images of coimmunofluorescence of intracellular staining of GABARAP (green) and CRT (red) in AMO1 WT cells untreated or treated with BTZ (5 nM; 10 hours). DAPI (4′,6-diamidino-2-phenylindole) was used to stain nuclei. An enlargement of the squared area shows colocalization with yellow fluorescence due to colocalizing signals; scale bars, 25 μm; enlargement scale bar, 10 μm. (I) Immunoblot of GABARAP, CRT, streptavidin, and GAPDH on total protein lysates and biotin pull-down proteins before and after doxycycline treatment (1 μg/mL; 24 hours) in AMO1, H929, and U266 CRT-3xHA-TurboID cells.